Simvastatin protects bladder and renal functions following spinal cord injury in rats

Anandakumar Shunmugavel1, Mushfiquddin Khan1, Peter C te Chou2, Ramanpreet K Dhindsa1, Marcus M Martin3, Anne G Copay3, Brian R Subach3, Thomas C Schuler3, Mehmet Bilgen2, John K Orak1 and Inderjit Singh*

Abstract
Background: Urinary bladder and renal dysfunction are secondary events associated with spinal cord injury (SCI) in humans. These secondary events not only compromise quality of life but also delay overall recovery from SCI pathophysiology. Furthermore, in experimental models the effects of SCI therapy on bladder and renal functions are generally not evaluated. In this study, we tested whether simvastatin improves bladder and renal functions in a rat model of experimental SCI.

Methods: SCI was induced by controlled contusion of T9-T10 in adult female rats. Simvastatin (5 mg/Kg body weight) was administered at two hours after SCI and repeated every 24 hours until the end point. Simvastatin-treated SCI animals (simvastatin group) were compared with vehicle-treated SCI animals (vehicle group) in terms of the Basso Beattie Bresnahan score, tissue morphology, cell death, and bladder/renal functions.

Results: The urinary bladder of vehicle animals showed a 4.3-fold increase in size and a 9-fold increase in wet weight compared to sham animals. Following SCI, the urine to plasma osmolality ratio increased initially but decreased 1 week after SCI. Hematoxylin and eosin staining of bladder tissue showed transitional epithelial hyperplasia, degeneration of lamina propria, and enlargement of tunica adventia in addition to detrusor muscle hypertrophy. Rats treated with simvastatin for 14 days displayed remarkable recovery by showing decreased bladder size and maintenance of a normal urine/plasma osmolality ratio, in addition to improved locomotion. The muscularis layer of the bladder also regained its compact nature in simvastatin animals. Moreover, SCI-induced renal caspase-3 activity was significantly decreased in the simvastatin group indicating the ability of simvastatin to reduce the renal tubular apoptosis.

Conclusion: Post-injury administration of simvastatin ameliorates bladder and renal dysfunction associated with SCI in rats.

Introduction
Spinal cord injury (SCI) results primarily in the loss of motor and sensory functions. Severe SCI often results not only in paralysis but also in the loss of sensation and reflexes below the point of injury, such as bowel and bladder control. Dysfunction of the urinary system is one of the most important consequences of SCI. Bladder dysfunction causes hyperarousal, sleep disturbances, and disruption of sensorimotor integration. Spinal and supraspinal circuitry controls urine storage and release [1,2]. Other brainstem nuclei like the raphe magnus, raphe pallidus, parapyramidal medullary reticular formation, subcoeruleus pars alpha, locus coeruleus and A5 and A7 nuclei are also involved in the bladder external urethral sphincter (EUS) pathway [3]. Signals from the pons project directly to the S2-S4 sacral segments of the spinal cord and control the detrusor and urethral sphincter activity parasympathetically, resulting in normal storage and voiding [4]. Detrusor-sphincter dyssynergia has been reported in SCI patients [5]. Understanding of bladder dysfunction comes from bladder outlet obstruction (BOO) [6-8] and experimental autoimmune encephalomyelitis (EAE) animal models [2]. Although bladder hypertrophy following SCI was reported previously [9], the bladder pathophysiology associated with SCI has not been thoroughly investigated. Since tissue hypertrophy depends on hypertrophying sig-

* Correspondence: singhi@musc.edu
1 Department of Pediatrics, Medical University of South Carolina, Charleston, SC, USA
Full list of author information is available at the end of the article

© 2010 Shunmugavel et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The pathophysiology of bladder dysfunction in SCI patients is significant. We investigated the pathophysiology of spinal bladder dysfunction in a rat contusion model of SCI. Contusion injuries are created by hitting the exposed spinal cord with a mechanical device that displaces the spinal cord by a preselected amount. The contusion injury model seems to be the most relevant to human spinal cord traumatic injury [11]. Current therapeutics for neurogenic bladder include functional electrical stimulation (FES) [12]; however, exposure to uncontrolled shock has been reported with delayed recovery to normal bladder function [13]. Other available treatment options include anticholinergics, self catheterization, and use of desmopressin, cannabinoids, vanilloids, and botulinum neurotoxin [14]. A bladder acellular matrix graft (BAMG) has also been shown to improve voiding function of SCI-induced hypertrophic bladder [15]. Despite the availability of various treatment options, catheterization is the most widely used technique in managing bladder problems with SCI patients. However, indwelling urethral catheterization is associated with complications like bladder stone formation or infection and causes significant morbidity [16]. Hence, catheter-free bladder maintenance is the ultimate aim of studies involving urogenital problems associated with SCI [17]. Furthermore, the direct effect of SCI therapies, including statins, on bladder and renal functions is not known. Therefore, this study investigates the therapeutic efficacy of simvastatin for restoring bladder and renal functions following SCI.

Statins are FDA-approved cholesterol lowering drugs widely used in clinical practice. Studies from our laboratory described anti-inflammatory properties of statins in a cell culture model [18]. Subsequently, studies from our laboratory and others have reported the immunomodulatory [19,20] and neuroprotective activities of statins in animal models of EAE [21,22]. These pleiotropic effects of statins were reported to function independently of their cholesterol lowering effects. Statins have also been reported to ameliorate the risk associated with metabolic syndrome in vascular and chronic kidney disease [23] as well as renal inflammatory diseases [24-27]. We observed neuroprotective and anti-inflammatory activities of atorvastatin in a post-injury treatment rat model of experimental SCI [28]. Since neurogenic bladder and renal dysfunction are associated with SCI and statin treatment has been reported to protect against SCI, we investigated the efficacy of simvastatin for bladder hypertrophy and renal dysfunction in a rat model of SCI.

Methods
Materials

Unless otherwise stated, all compounds were purchased from Sigma-Aldrich (St. Louis, MO, USA). Caspase 3 antibody (rabbit polyclonal) was from Santa Cruz, CA, USA. Simvastatin was purchased from Calbiochem, CA, USA.

Animal

The animals used in the present study were female Sprague-Dawley rats (225-250 g) purchased from Harlan laboratories (Durham, NC). The animal procedures for the study were approved by the Institutional Animal Care and Use Committee (IACUC) of the Medical University of South Carolina.

Experimental design and administration of simvastatin

The experiment consisted of three groups of animals: sham operated (sham), vehicle-treated (vehicle), and simvastatin-treated (simvastatin). Simvastatin (5 mg/kg in 1% methyl cellulose solution) was gavage fed to the animals at 2 hours after SCI and every 24 hours thereafter until the animals were sacrificed. Vehicle and sham animals were fed with carrier solution alone. Selection of 5 mg/kg dose of simvastatin is based on our earlier study on atorvastatin-mediated neurovascular protection following SCI in rats [28].

Controlled contusion spinal cord injury

Animals were anesthetized with ketamine-xylazine cocktail (80 mg/kg-10 mg/kg body weight respectively). After confirming the validity of anesthesia by toe pinching, the animals were depilated on dorsal spine line, and a hemilaminectomy was done at the T9-T10 level to expose the dura overlaying the spinal cord [29]. Spinal cord contusion injury was induced by a controlled contusion injury (CCI) device described by Bilgen [30]. Injury was made with 2 mm diameter impactor at 1.5 m/s velocity to a depth of 1 mm for 85 msec. Following SCI, the wound was irrigated with phosphate buffered saline (PBS) solution, and the incision was closed in layers, with the skin closed using polysorb 4. Sham-operated animals underwent laminectomy only. Animals were returned to their cages and kept on a 37°C heating blanket overnight.

Evaluation of locomotor function

The locomotor activities of rats were recorded for 28 days according to the Basso Beattie Bresnahan (BBB) open field expanded locomotor rating scale [31]. The BBB rating was described with a 21-point scale to measure hind limb function at various time points after injury. The scale assesses 10 different categories, including limb movement and tail position. Sham operated animals scored 21 on the BBB scale, whereas the SCI animals with complete hind limb paralysis scored 0. Experimental animals were tested after SCI on days 3, 7, 14, 21, and 28. Each group consisted of at least 6 animals. Evaluations were made by two investigators blinded to the experimental groups.
Bladder analyses
Bladders of experimental animals were emptied by gentle abdominal massage. At indicated times following SCI, the animals were sacrificed with intra peritoneal injections of sodium pentobarbital. After proper bladder emptying, they were perfused with PBS followed by neutral formalin solution. The bladders were extracted, weighed and preserved in 10% formalin (Fisher, Pittsburgh, PA, USA) for further fixation. Images of bladders were scanned, and the area of the images was calculated using BioRad Quantity One 4.6.5 image analysis software.

Urine analyses
Animals were given abdominal massage to empty the bladder three times a day at 8.00, 13.00 and 20.00 hrs regularly, and the 12 h urine was used to measure volume, osmolality, and protein level. Osmolality was measured with a Microsmette (freezing point depression osmometry) instrument per the instructions of the manufacturer (Precision systems Inc, MA, USA). Each sample was measured in triplicate. Urine protein concentration was measured by the Bradford protein assay method. Plasma collected from 100 μl blood from the caudal vein was also analyzed in the same way.

Histology
At designated time points, the animals were anesthetized with intra peritoneal injections of sodium pentobarbital and then transcardially perfused with PBS followed by neutral formalin solution. Bladder and kidney tissues were removed and fixed in 10% formalin solution. After fixation, the tissues were processed following routine histological procedures. Tissues were dehydrated in series of alcohol and infiltrated with paraffin wax (M.P 60°C) using Leica TP-1020 automatic tissue processor. Tissue blocks were sectioned (8 μm) with Leica HM-325 rotary microtome. Sections were adhered on to super frost plus gold microscope slides. Sections for morphological studies were processed and stained with hematoxylin and eosin (H&E) as described previously [32].

Immunofluorescence study
Deparaffinized and rehydrated slides were boiled in antigen unmasking solution (Vector Labs, Burlingame, CA) for 10 min, cooled for 20 min, and washed with Tris-sodium buffer (0.1 M Tris-HCl, pH-7.4, and 0.15 M NaCl) with 0.05% Tween 20 (TNT) three times each for 5 min. The sections were then treated with trypsin (0.1% for 10 min). Endogenous peroxidase activity was eliminated by treating the section with 3% hydrogen peroxide solution for 10 min. Sections were blocked in TNT buffer with 0.5% blocking reagent (TNB, supplied with TSA-Direct kit; NEN Life Sciences, Boston MA) for 30 min to reduce nonspecific staining. The sections were incubated overnight with anti caspase-3 antibody (Santa Cruz, CA, USA; 1:200) at 4°C. After washing with PBS, the sections were stained with Alexafluor 488 (Molecular Probes, Invitrogen, CA, USA) fluorophore conjugated secondary antibody. The tissue fluorescence pattern was observed and recorded with a Leica TCS SP5 Laser scanning microscope.

Statistical analysis
Statistical analysis was performed by student t test using Graph pad -software. Data are expressed as mean ± standard deviation (SD). P < 0.05 was considered statistically significant.

Results
Simvastatin improves locomotor behavior in SCI rats
SCI is associated with apoptotic neuronal loss resulting in compromised locomotor functions. We confirmed the severity and consistency of SCI by the paraplegic outcome of the experimental animals. The effect of simvastatin in restoring locomotor behavior was evaluated by BBB score after SCI. The sham animals consistently scored 21 on the BBB locomotor scale. The vehicle treated group scored 0.57 ± 0.2 (day 3), 2.78 ± 0.93 (day 7), 6.08 ± 0.39 (day 14), 6.33 ± 0.35 (day 21), and 6.417 ± 0.41 (day 28) post SCI. The simvastatin group scored significantly higher (1.71 ± 0.612, 5.583 ± 0.69, 9.33 ± 0.9, 9.92 ± 1.2, and 10.58 ± 1.3 on day 3, 7, 14, 21, and 28 post SCI, respectively) than the vehicle group animals.

Simvastatin reduces the size and weight of urinary bladder in SCI rats
Bladder size and weight changed significantly in animals with SCI (Fig 1). The bladder weighed 0.115 ± 0.22 g in the sham animals, whereas it was 1.05 ± 0.26 g in SCI animals, and the increase grew to 9-fold on day 14 after SCI. The simvastatin treated group of animals had only a 2.7 fold increase in bladder weight compared to the sham animals (Fig 1A). Bladder volume in terms of area also significantly increased in the vehicle group (888.582 ± 12.42 mm²). The increase in bladder volume compared to the sham group was 4.29-fold. The simvastatin-treated group had only a 1.85-fold increase in bladder area compared to the sham group (Fig 1B). In contrast, no significant difference in body weight loss between vehicle and simvastatin groups was observed during the experimental period (Fig 2).
Simvastatin ameliorates voided volume, osmolality, and protein level of urine in SCI rats

The volume of voided urine in the bladder gradually decreased from day 1 to day 14 in SCI rats (Fig 3). The sham animals retained less than 70 μl of urine. Vehicle animals retained 1.2 ± 0.13 ml on day 14 after SCI, whereas simvastatin animals retained a significantly lower volume of urine (0.53 ± 0.01 ml) in the bladder. The change in urine to plasma osmolality ratio associated with SCI is given in Fig 4. Sham animals showed a ratio of 6.1 to 7.5 during the study period. The ratio ranged from 3.6 to 38.6 in the vehicle group. Vehicle animals showed a significant increase in the ratio. The simvastatin group of animals showed increasingly high urine/plasma osmolality ratios for 3 days after SCI. Later, the ratio decreased gradually and maintained the levels observed in sham animals. The quantity of protein excreted through urine was significantly elevated in vehicle animals. (Fig 5). The urine/plasma protein ratio was 0.124 ± 0.03 in sham animals. In the vehicle animal, the ratio increased to 1.03 ± 0.3 and 3.887 ± 0.45 on day 7 and 14, respectively. The

Simvastain decreases weight and area of bladder after SCI in rats

Wet weight (A) and area (B) of bladder of sham, vehicle and simvastatin groups were determined at 14 days after SCI. Data are expressed as mean ± SD, n = 7. **p < 0.01 vs. sham, ## p < 0.01 vs. vehicle.
Simvastatin group showed significantly lower levels of protein excreted in urine on day 7 as well as day 14 after SCI.

Simvastatin improves SCI-induced bladder and renal histopathology in SCI rats
In the sham animal bladder, the transitional epithelial layer was about 3 cell layers thick and was covered with membrane plaque as shown in Fig 6a. The muscular layer was thick and compact (Fig 6b). Tunica adventia was thin and closely applied to the outer circular muscle layer of the bladder (Fig 6c). In the hypertrophied bladder of the vehicle treated animals, the transitional epithelial cells were several layers thick due to hyperplasia and also lacked proper organization (Fig 6d). Lamina propria was highly degenerated and was characterized by infiltration of cells (Fig 6e). The muscularis layer was highly disorganized, and the number of nuclei per muscle area was also decreased. The hypertrophied bladder was also characterized by thick and disorganized tunica adventia, and cellular infiltration was evident (Fig 6f). Simvastatin treatment showed remarkable recovery in terms of a reduced number of transitional epithelial cell layers and diminished infiltration of cells (Fig 6g). The muscularis layer was also compact (Fig 6h), while the tunica adventia thickening and disorganization observed in the vehicle treated group was significantly reduced in the simvastatin group (Fig 6i).

Simvastatin improves tissue structure and reduces the expression of caspase-3 in kidney from SCI rats
The kidney of the sham group showed normal renal tubules and glomerular complexes with the glomerular complex clear and devoid of any filtrate accumulation (Fig 7a). The renal tubules from the vehicle animals showed a remarkable degeneration. An accumulation of filtrate in the glomerular complex was also evident (Fig 7b). In addition, the SCI kidney showed crystals in the intratubular space. Degeneration of the glomerular wall was also seen (Fig 7c). The simvastatin animals showed clear renal tubules (Fig 7d). Glomeruli were without accumulation of any filtrate. Renal tubular degeneration was also reduced (Fig 7e). Next, we examined the expression of caspase-3, an indicator of the apoptotic mechanisms of renal tubular epithelial cell loss (Fig 8). Insignificant staining observed in the sham kidney indicates the absence of caspase-3 activity (Fig 8A). The vehicle kidney showed increased caspase-3-positive renal tubules (Fig 8B), while simvastatin treatment significantly reduced the expression of caspase-3 in renal tubules (Fig 8C).

Discussion
The present study shows that post-SCI treatment with simvastatin not only reduced the severity of SCI but also attenuated SCI-induced pathological damage to the bladder and kidney in rats. The improvements in voided urine volume, osmolality of urine, and proteinuria correlated with recovery of locomotor function in simvastatin-treated animals. The post-SCI period is marked by reduced locomotor activity, an increased catabolic rate, and nitrogen loss. In the present study, we observed a 9-fold increase in bladder weight induced by SCI among controls while the animals treated with simvastatin showed only a 2.7-fold increase in bladder weight. The nature of bladder hypertrophy is dependent on specific hypertrophying signals; for example, SCI-induced spinal bladder is characterized by smooth muscle cell hypertrophy of the bladder [9], but alloxan-induced bladder hypertrophy does not involve smooth muscle hypertrophy [33]. The outlet obstruction model induced about a 4-fold increase in rat bladder weight [34] and a 6-fold increase in bladder volume at 3 days after SCI [35]. In addition to weight increase, we also observed increased hyperplasia of the transitional epithelial layer and enlarged tunica adventia in the spinal bladder. The differing relationship observed between the severity of hypertrophy and the hypertrophying signals emphasizes that SCI-induced bladder hypertrophy needs to be studied as an independent pathology. In addition, as SCI patients also show simultaneous contraction of the detrusor and sphincter, resulting in detrusor-sphincter dyssynergia accompanied by urinary retention and increased bladder volume [5], the animal model used in the present study fits well for the purpose of delineating SCI-induced bladder abnormalities as observed in human patients. The increase in the urine-to-plasma osmolality ratio observed in the present study reflects a reduction in
glomerular filtration level [36]. Osmolality reflects the dehydration and hydration status of the individual [37]. Under pathological conditions, low urine osmolality is seen with acute renal failure [38] and nephrotoxicity [39]. Protein excreted in urine reflects the functional status of the kidney [40]. The high urine/plasma protein ratio of SCI animals was significantly reduced by simvastatin treatment. Statins have previously been reported to decrease proteinuria and enhance the glomerular filtration rate in patients with chronic kidney disease [41,42]. Buemi et al have shown fluvastatin to reduce proteinuria in IgA nephropathy patients [43]. Damage to glomeruli and increased infiltration were evident in the hypertrophying bladders of SCI animals, and the degree of damage was less pronounced in the simvastatin group (Fig 7). This reduced glomerular damage may occur through the direct effect of statins on mesangial cells [44]. Observed recovery of the spinal reflex of bladder following SCI has varied from 7 [9] to 14 days [4]; however, despite recovery of spinal reflex, complete voiding efficiency was not recovered [45]. The increased pressure due to retention of a large volume of urine in the bladder forces the urine back into the ureter and hilus of the kidney, thus disturbing the renal medulla [46] and the cortico-medullary interstitial gradient, affecting urine concentration [47]. Hence, with increased urine retention and proteinuria, we anticipated that bladder hypertrophy would affect normal renal architecture. Histological and immunofluo-

Figure 6 Simvastatin improves histomorphology of spinal bladder evaluated at 14th day after SCI in rats. Histomorphology of spinal bladder of sham (a–c), vehicle (d–f) and simvastatin group (g–i) was determined by H & E staining. The transitional epithelium was 3 cell layers thick in sham and covered with membrane plaque (a, arrow). Hyperplasia and degeneration of epithelial layer and degeneration of lamina propria were observed in spinal bladder (d). Muscle layers were thick with little matrix in sham control (b) but degenerated with large matrix deposition in spinal bladder (e, arrow). Tunica adventia enclosed large space filled with matrix in spinal bladder (f). Simvastatin treatment significantly decreased the transitional epithelial hyperplasia (g) muscular hypertrophy (h) and matrix in tunica adventia (i, arrow). Photomicrographs are representative of n = 3 in each group. Magnification × 400.
rescence studies with kidney (Fig 7 & 8) supported this assumption. Degeneration of plaques as observed in spinal bladder has serious consequences because the urothelium, in addition to serving as a passive barrier between urine and detrusor muscle, is involved in antigen presentation, micturition reflex, and inflammatory regulation [48]. Simvastatin treatment preserved the membrane plaques and protected the underlying urothelium. The simvastatin group showed a decreased level of crystals in the kidney (Fig 7d, e). This observation is interesting as humans and rats have similar crystal-clearing mechanisms [49]. In addition, statins have already been shown to inhibit renal crystal formation in rats [24]. Renal inflammation is one of the factors responsible for stone formation [50]. Anti-inflammatory and neuroprotective properties of statins are now well established [18, 29, 51]. Therefore, the reduced number of caspase 3 positive cells in simvastatin-treated rats supports earlier studies of reduced cell death by rosuvastatin [52] and atorvastatin (22). However, the link between locomotion recovery and damage to bladder and kidney following SCI is not clear. Our data indicate that the degree of bladder/kidney dysfunction and their recovery are dependent on the severity of injury and the associated myelin/white matter loss at the injury site [4]. Simvastatin-mediated recovery of bladder dysfunction may be due, at least in part, to enhanced neuroprotection within the spinal cord. Increased recovery of locomotor behavior and improved renal/bladder functions in simvastatin-treated animals supported the overall efficacy of simvastatin therapy in SCI. In addition, atorvastatin was also reported to attenuate SCI-induced blood spinal cord barrier (BSCB) leakage [28]. We have used several statins, including lovastatin, simvastatin and

Figure 7 Simvastatin improves histomorphology of kidney evaluated at 14th day after SCI in rats: Histomorphology of kidney of sham (a) vehicle (b, c) and simvastatin (d, e) groups was determined by H & E staining. Histology of glomerular complex (arrow) and renal tubules in sham kidney was normal. Bladder hypertrophy results in renal tubular degeneration and glomerular dysfunction (b) and formation of crystals (arrow heads) and degeneration of glomerular wall (arrow) in spinal bladder kidneys (c). Simvastatin treatment significantly reduced the damage observed with renal tubules and glomerular complex (d & e arrows). Photomicrographs are representative of n = 3 in each group. Magnification (a × 400 and b–e × 600).
atorvastatin, interchangeably with comparable effects in animal models of neuroinflammatory diseases, suggesting a class effect of HMG-CoA reductase inhibitors. They exert significant effects on oxidative stress and inflammation within a few hours. However, pleiotropic effects on endothelial functions seem to appear earlier for simvastatin than for atorvastatin. Although the half-life of atorvastatin is longer (~7 h) [53] than simvastatin (~4.5 h) [54], simvastatin’s lipophilic qualities determines its superior tissue accessibility, thus making it especially promising for longer treatment regimens when inflammation is diminishing, but repair and recovery are in progress. Therefore, simvastatin (5 mg/kg) was elected in this study. The dose 5 mg/kg was based on studies with atorvastatin in rat SCI models [28,55]. Lower dose such as 0.5 mg/kg of simvastatin significantly improves functional outcome in a rat model of traumatic brain injury [56]. Higher dose of simvastatin (20 mg/kg) is reported to be toxic in experimental SCI studies [57].

The early recovery of a bladder contraction reflex in simvastatin-treated animals may also be due to the effect of the drug on the spinal bladder itself. For example, induction of inositol 1,4,5 triphosphate (IP3) stimulates the initial contractile response of bladder smooth muscle [58], and simvastatin has been shown to increase the cellular level of IP3 [59]. Nevertheless, bladder hypertrophy involves several factors, including M2 receptors [60], neurotransmitters like glutamate [61], transcriptional factors like STAT3 [6], nerve growth factor [62], intracellular calcium [34], transforming growth factor beta [63], basic fibroblast growth factor [7], and protein kinase C [64]. Therefore, the exact signaling cascade involved in simvastatin-mediated bladder and renal functional recovery remains to be elucidated. Nonetheless, the overall beneficial effects of statins indicate their potential for effecting quick clinical benefits in aiding tissue repair.

**Conclusions**

The present study suggests that treating SCI patients with simvastatin may help to ameliorate bladder and renal dysfunction in addition to providing recovery of locomotor functions.

**List of Abbreviations**

BAMG: bladder acellular matrix graft; BBB: Basso Beattie Bresnahan; BOO: bladder outlet obstruction; BSCB: blood spinal cord barrier; CCI: controlled contusion injury; EAE: experimental autoimmune encephalomyelitis; EUS: external urethral sphincter; FDA: food and drug administration; FES: functional electrical stimulation; H&E: hematoxylin and eosin; IACUC: institutional animal care and use committee; IP-3: inositol 1,4,5 triphosphate; PBS: phosphate buffered saline; SCI: spinal cord injury; SD: standard deviation; STAT3: signal transducer and activator of transcription 3.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

This study is based on an original idea of AS, MK and IS. MK and AS wrote the manuscript. AS, PCC, RKD, MB carried out animal and biochemical studies. AS, MM, AGC, BRS, TCS performed histochemical studies. JKO critically examined renal and bladder studies and corrected the manuscript. All authors have read and approved the manuscript.

**Acknowledgements**

This work was supported by grants NS-22576, NS-34741 and NS-37766 and DC00422, 07506x from the NIH, CO6 RR018823 and CO6 RR0015455 from the Intramural Research Facilities Program of the National Center for Research Resources and grant from The Spinal Research Foundation VA. We thank Dr. Eric Buck, Department of Pharmacology, for help in osmolality measurement, Dr. Hainan Lang and Liu Liya Department of Pathology and Laboratory Medicine for help in histology, Dr. Phillip D. Bell, Department of Nephrology, for constructive criticisms, Dr. Peter Komlosi for help in confocal facility and Dr. Miguel Contreras for help in imaging. We acknowledge Joyce Bryan for her help in animal procurement. We are grateful to Dr. Tom Smith from the MUSC Writing Center for his valuable editing and correction of the manuscript.
References

1. de Groat WC. Central neural control of the lower urinary tract. Ciba Found Symp 1990; 151:27-44.
2. Vignes JR, Deloire M, Petry K. Animal models of sacral neuremodulation for detrusor overactivity. Neurourol Urodyn 2009, 288-12.
3. Vizzard MA, Erickson VL, Card JP, Ropollo JR, de Groat WC. Transneuronal labeling of neurons in the adult rat brainstem and spinal cord after injection of pseudorabies virus into the urethra. J Comp Neurol 1995, 355:629-640.
4. Pikov V, Wrathall JR. Coordination of the bladder detrusor and the external urethral sphincter in a rat model of spinal cord injury: effect of injury severity. J Neurosci 2001, 21:559-569.
5. Chang S, Mao ST, Hu SJ, Lin WC, Cheng CL. Studies of detrusor-sphincter synchry and dyssynergy in rats with spinal cord injury via fractional Brownian motion. IEEE Trans Biomed Eng 2000, 47:1066-1073.
6. Fujita O, Asanuma M, Yokoyama T, Miyazaki K, Ogawa N, Kumon H. Involvement of STAT3 in bladder smooth muscle hypertrophy following bladder outlet obstruction. Acta Med Okayama 2006, 60:299-309.
7. Imamura M, Kanematsu E, Yamamoto S, Kimura Y, Kanatani I, Ito N, Tabata Y, Ogawa O. Basic fibroblast growth factor modulates proliferation and collagen expression in urinary bladder smooth muscle cells. Am J Physiol Renal Physiol 2007, 293:F1007-1017.
8. Lassmann J, Slivovski J, Chang A, Canning DA, Zderic SA. Deletion of one SERCA2 allele confers protection against bladder wall hypertrophy in a murine model of partial bladder outlet obstruction. Am J Physiol Renal Physiol 2008, 294:F588-66.
9. Mimata H, Satoh F, Tanigawa T, Nomura Y, Ogata J. Changes of rat urinary bladder during acute phase of spinal cord injury. Urol Int 1993, 51:89-93.
10. Schwartz K, Boehler RK, de la Bastie D, Lompre AM, Mercadier JJ. Switches in cardiac muscle gene expression as a result of pressure and volume overload. Am J Physiol 1992, 262:E351-359.
11. Metz GA, Curt A, Meent van de, Klusman I, Schwab ME, Dietz V. Validation of the weight-drop contusion model in rats: a comparative study of human spinal cord injury. J Neurotrauma 2000, 17:1-17.
12. Radziszewski K, Zielinski H, Radziszewski P, Swiecicki R. Transcutaneous electrical stimulation of urinary bladder in patients with spinal cord injuries. Eur Neurol 2009, 51:397-403.
13. Grau JW, Washburn SN, Hook MA, Ferguson AR, Crown ED, Garcia G, Bolding KA, Miranda RC. Uncontrollable stimulation undermines recovery after spinal cord injury. J Neurotrauma 2004, 21:1795-1817.
14. Kalsi V, Fowlie CJ. Therapy Insight: bladder dysfunction associated with multiple sclerosis. Nat Clin Pract Neurol 2005, 1:492-501.
15. Utakami S, Shina H, Enokida H, Kawamoto K, Kikuno N, Fandel T, Vejdani K, Cologna A, Martins AC. Long term evaluation of functional and morphological bladder changes of rat urinary bladder during acute phase of spinal cord injury. Urol Int 2007, 25:207-213.
16. Nagashima M, Tazini T, Tanaka K. [A clinical study of bladder stone with spinal cord injury in paediatric age]. Hinyokika Kiyo 2008, 54:647-650.
17. Jami F. Towards a catheter free status in neurogenic bladder dysfunction: a review of bladder management options in spinal cord injury (SCI). Spinal Cord 2001, 39:355-361.
18. Pahan K, Sheikh FG, Nambudiri AM, Singh I. Lovastatin and phenylephrine inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest 1997, 100:2851-2859.
19. Weber M, Zawilski SS. Statins and demyelination. Curr Opin Neurol 2008, 318:313-324.
20. Nath N, Ghai S, Prasad R, Singh A, Singh I. Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy. J Immunol 2004, 172:1273-1286.
21. Stanislaus R, K P, Singh AK, Singh I. Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin. Neurosci Lett 1999, 268:271-74.
22. Painlia A, M P, Singh I, Singh AK. Combined medication of lovastatin with rolipram suppresses severity of experimental autoimmune encephalomyelitis. Exp Neurol 2008, 214:681-180.
23. Athyros VG, Mikhailidis DP, Liberopoulos EN, Kakafika AI, Karagiannis A, Papageorgiou AA, Tzolos K, Gkanakis E, Elafis M. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GERek Atorvastatin and Coronary Heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007, 22:118-127.
24. Fuhata M, Momohara C, Yoshio I, Tsujimura A, Nonomura N, Okuyama A. Atorvastatin inhibits renal crystal retention in a rat stone forming model. J Urol 2008, 180:2212-2217.
25. Zhou MS, Schuman IH, Jaimes EA, Raj L. Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin with concomitant increase in nitric oxide bioavailability. Am J Physiol Renal Physiol 2008, 295:F53-59.
26. Lin CL, Cheng H, Tong CW, Huang WJ, Chang PI, Yang JT, Wang YJ. Simvastatin reverses high glucose-induced apoptosis of mesangial cells via modulation of Wnt signaling pathway. J Am J Physiol 2008, 289:290-297.
27. Carrero J, Miyi Y, B, Lanvin P. Cytokine dysregulation in chronic kidney disease: how can we treat it? Blood pump 2008, 26:291-299.
28. Pann R, Christie D, Barbosa E, Singh I, Singh AK. Post-trauma Lipitor treatment prevents endothelial dysfunction, facilitates neuroprotection, and promotes locomotor recovery following spinal cord injury. J Neurochem 2007, 101:182-200.
29. Pann R, Barbosa E, Singh I, Singh AK. Attenuation of acute inflammatory response by atorvastatin after spinal cord injury in rats. J Neurosci Res 2007, 79:34-350.
30. Billen V. A new device for experimental modeling of central nervous system injuries. Neurorehabil Neural Repair 2005, 19:219-226.
31. Basso MS, Beattie M, Bresnahan JC. A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma 1995, 12:21-27.
32. Kiemann J. Interactions between mast cells and nerves. Neurogenic inflammation. Trends Pharmacol Sci 1990, 11:316.
33. Rodrigues A, Suaid H, Tucci S, Fazan V, Fois M, Cologna A, Colonna A, Martins AC. Long term evaluation of functional and morphological bladder alterations on alloxa-induced diabetes and aging: experimental study in rats. acta cir bras 2008, 23:53-58.
34. Amer A, Sujve Scott R, Haase H, Morano I, Uvelius B. Intracellular calcium in hypertrophic smooth muscle from rat urinary bladder. Scand J Urol Nephrol 2001, 35:280-287.
35. Biglen E. Urinary retention in women. BJU Int 2003, 91:463-464.
36. Planas M, Wachtel T, Frank H, Henderson LW. Characterization of acute renal failure in the burned patient. Arch Intern Med 1982, 142:2087-2091.
37. Leech S, Penney MD. Correlation of specific gravity and osmolality of urine in neonates and adults. Arch Dis Child 1987, 62:671-673.
38. Wilson DH, Honrath U. Inner medullary collecting duct function in ischemic acute renal failure. Clin Invest Med 1988, 11:157-166.
39. Polycarp E, Arnold L, Schmitt E, Duvillard L, Ferrant E, Isambert N, Duvillard C, Beltramino JL, Chevet D, Chauffert B. Low urine osmolality as a determinant of cisplatin-induced nephrotoxicity. Int J Cancer 2004, 111:131-137.
40. Gay M, Newall R, J B, Pa K, Price C. Use of a first-line urine protein-to-creatinine ratio strip test on random urines to rule out proteinuria in patients with chronic kidney disease. Nephrol Dial Transplant 2009, 24:1189-1193.
41. Nakamura T, Ushiyama C, Hirokawa K, Osada S, Inoue T, Shimada N, Koide H. Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis. Nephrol Dial Transplant 2002, 17:289-302.
42. Agawal R. Effects of statins on renal function. Am J Cardiol 2006, 97:478-755.
43. Buemi M, Allegria A, Corica F, Alosi C, Giacobbe M, Pettinato G, Corsonello A, Senatore M, Amin H, Benet A, Frisina N. Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy. Nephron 2000, 86:427-431.
